Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas.

MLA

Rosenbaum, Evan, et al. “Immune-Related Adverse Events after Immune Checkpoint Blockade-Based Therapy Are Associated with Improved Survival in Advanced Sarcomas.” Cancer Research Communications, vol. 3, no. 10, Oct. 2023, pp. 2118–25. EBSCOhost, https://doi.org/10.1158/2767-9764.CRC-22-0140.

APA

Rosenbaum, E., Seier, K., Bradic, M., Kelly, C., Movva, S., Nacev, B. A., Gounder, M. M., Keohan, M. L., Avutu, V., Chi, P., Thornton, K. A., Chan, J. E., Dickson, M. A., Donoghue, M. T. A., Tap, W. D., Qin, L.-X., & D’Angelo, S. P. (2023). Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas. Cancer Research Communications, 3(10), 2118–2125. https://doi.org/10.1158/2767-9764.CRC-22-0140

Chicago

Rosenbaum, Evan, Kenneth Seier, Martina Bradic, Ciara Kelly, Sujana Movva, Benjamin A Nacev, Mrinal M Gounder, et al. 2023. “Immune-Related Adverse Events after Immune Checkpoint Blockade-Based Therapy Are Associated with Improved Survival in Advanced Sarcomas.” Cancer Research Communications 3 (10): 2118–25. doi:10.1158/2767-9764.CRC-22-0140.